Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of INV-101 in Healthy Adults
NCT06938204Phase 1Completed
- Sponsor
- Innovo Therapeutics
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zevaquenabant in ulcerative colitis (UC) (6 arms), sponsored by Innovo Therapeutics. Primary endpoint: Safety Analysis. Started Apr 2024; status: completed.
02
Drugs
zevaquenabant
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06938204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938204.